Caspase structure, proteolytic substrates, and function during apoptotic cell death.

Nicholson DW

Cell Death Differ, (11):1028-1042 1999

MED: 10578171

From bench to clinic with apoptosis-based therapeutic agents.

Nicholson DW

Nature, (6805):810-816 2000

MED: 11048733

Solid phase synthesis of selective caspase-3 peptide inhibitors.

Grimm EL, Roy B, Aspiotis R, Bayly CI, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Tawa P, Vaillancourt JP, Xanthoudakis S, Zamboni RJ

Bioorg Med Chem, (5):845-851 2004

MED: 14980595

Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors.

Han Y, Giroux A, Grimm EL, Aspiotis R, Francoeur S, Bayly CI, Mckay DJ, Roy S, Xanthoudakis S, Vaillancourt JP, Rasper DM, Tam J, Tawa P, Thornberry NA, Paterson EP, Garcia-Calvo M, Becker JW, Rotonda J, Nicholson DW, Zamboni RJ

Bioorg Med Chem Lett, (3):805-808 2004

MED: 14741294

Nicotinyl aspartyl ketones as inhibitors of caspase-3.

Isabel E, Black WC, Bayly CI, Grimm EL, Janes MK, McKay DJ, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Thornberry NA, Vaillancourt JP, Xanthoudakis S, Zamboni R

Bioorg Med Chem Lett, (13):2137-2140 2003

MED: 12798321

Title not supplied

Chen

Can. J. Chem. 1987

Title not supplied

Webb

J. Am. Chem. Soc. 1992

Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide.

Roy S, Bayly CI, Gareau Y, Houtzager VM, Kargman S, Keen SL, Rowland K, Seiden IM, Thornberry NA, Nicholson DW

Proc Natl Acad Sci U S A, (11):6132-6137 2001

MED: 11353841

Charge optimization leads to favorable electrostatic binding free energy.

Kangas E, Tidor B

Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics, (5 Pt B):5958-5961 1999

MED: 11969577

Title not supplied

Davies

J. Organomet. Chem. 1990